HPV Clinical Trial
Official title:
Actions For Collaborative Community Engaged Strategies for HPV (ACCESS-HPV)
In the current pilot study, Actions for Collaborative Community-Engaged Strategies for HPV (ACCESS-HPV), investigators will use participatory crowdsourcing methods to drive HPV prevention among mother-daughter dyads. Crowdsourcing open calls will allow us to identify locally relevant messages and dissemination techniques to increase uptake of HPV prevention. Then, participatory learning communities will build capacity for community led implementation of selected strategies. Informed by social learning theory and the PEN-3 cultural model, our multi-disciplinary research team proposes the following specific aims: (1) to develop a new combined campaign to increase HPV vaccination for young girls (ages 9-14) and HPV self-collection for mothers (ages 30-65) using crowdsourcing open calls and participatory learning communities; and (2) to determine the preliminary effectiveness of, seven crowdsourced campaign on uptake of HPV vaccination among young girls/women and HPV self-collection among their mothers. Our primary outcome will be HPV vaccine uptake (ascertained by clinic records of vaccine uptake) among young girls and HPV self-collection (ascertained by laboratory receipt of specimens) among their mothers. The strong support of the Nigerian Institute for Medical Research (NIMR) alongside national HPV programs creates a rich research infrastructure and increases the likelihood of successful implementation. Our multi-disciplinary research team has experience organizing implementation research focused on crowdsourcing and community participation in Nigeria. This pilot study will enhance our understanding of HPV prevention in resource-constrained settings.
Status | Recruiting |
Enrollment | 350 |
Est. completion date | December 1, 2024 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 9 Years to 65 Years |
Eligibility | Inclusion Criteria: - Female - Both the mothers'/caregivers' (between ages 30-65 years) and daughters' (Between 9 to 14 years) willingness to participate in the study - All participants must agree to an informed consent in English - Parental guardian's cell phone number for follow-up and/or retention Exclusion Criteria: Inability to comply with study protocol - Illness, cognitive impairment or threatening behavior with acute risk to self or others - No informed consent or cell phone |
Country | Name | City | State |
---|---|---|---|
Nigeria | Nigerian Institute of Medical Research | Yaba | Lagos |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | Nigerian Institute of Medical Research, University of North Carolina, Chapel Hill |
Nigeria,
Abuelo CE, Levinson KL, Salmeron J, Sologuren CV, Fernandez MJ, Belinson JL. The Peru Cervical Cancer Screening Study (PERCAPS): the design and implementation of a mother/daughter screen, treat, and vaccinate program in the Peruvian jungle. J Community Health. 2014 Jun;39(3):409-15. doi: 10.1007/s10900-013-9786-6. — View Citation
Amponsah-Dacosta E, Kagina BM, Olivier J. Health systems constraints and facilitators of human papillomavirus immunization programmes in sub-Saharan Africa: a systematic review. Health Policy Plan. 2020 Jul 1;35(6):701-717. doi: 10.1093/heapol/czaa017. — View Citation
Campos NG, Demarco M, Bruni L, Desai KT, Gage JC, Adebamowo SN, de Sanjose S, Kim JJ, Schiffman M. A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer. Prev Med. 2021 Mar;144:106438. doi: 10.1016/j.ypmed.2021.106438. Epub 2021 Mar 4. — View Citation
Cates JR, Shafer A, Diehl SJ, Deal AM. Evaluating a County-Sponsored Social Marketing Campaign to Increase Mothers' Initiation of HPV Vaccine for their Pre-teen Daughters in a Primarily Rural Area. Soc Mar Q. 2011 Spring;17(1):4-26. doi: 10.1080/15245004.2010.546943. — View Citation
Devarapalli P, Labani S, Nagarjuna N, Panchal P, Asthana S. Barriers affecting uptake of cervical cancer screening in low and middle income countries: A systematic review. Indian J Cancer. 2018 Oct-Dec;55(4):318-326. doi: 10.4103/ijc.IJC_253_18. — View Citation
Lee H, Kim M, Cooley ME, Kiang PN, Kim D, Tang S, Shi L, Thiem L, Kan P, Peou S, Touch C, Chea P, Allison J. Using narrative intervention for HPV vaccine behavior change among Khmer mothers and daughters: A pilot RCT to examine feasibility, acceptability, and preliminary effectiveness. Appl Nurs Res. 2018 Apr;40:51-60. doi: 10.1016/j.apnr.2017.12.008. Epub 2017 Dec 18. — View Citation
Lim JN, Ojo AA. Barriers to utilisation of cervical cancer screening in Sub Sahara Africa: a systematic review. Eur J Cancer Care (Engl). 2017 Jan;26(1). doi: 10.1111/ecc.12444. Epub 2016 Feb 7. — View Citation
McFarland DM, Gueldner SM, Mogobe KD. Integrated Review of Barriers to Cervical Cancer Screening in Sub-Saharan Africa. J Nurs Scholarsh. 2016 Sep;48(5):490-8. doi: 10.1111/jnu.12232. Epub 2016 Jul 19. — View Citation
Scarinci IC, Hansen B, Kim YI. HPV vaccine uptake among daughters of Latinx immigrant mothers: Findings from a cluster randomized controlled trial of a community-based, culturally relevant intervention. Vaccine. 2020 May 22;38(25):4125-4134. doi: 10.1016/j.vaccine.2020.03.052. Epub 2020 Apr 27. — View Citation
Winer RL, Gonzales AA, Noonan CJ, Buchwald DS. A Cluster-Randomized Trial to Evaluate a Mother-Daughter Dyadic Educational Intervention for Increasing HPV Vaccination Coverage in American Indian Girls. J Community Health. 2016 Apr;41(2):274-81. doi: 10.1007/s10900-015-0093-2. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Key Implementation Factors | Guided by the RE-AIM framework for implementation science, semi-structured, in-depth interviews will be conducted at the individual and setting levels to explore the factors associated with the implementation of the intervention (e.g., reach, adoption, implementation, and maintenance). | Up to 8 weeks | |
Primary | Uptake of HPV Vaccination Over the 8 weeks follow-up | Proportion of eligible girls who receive at least one dose of HPV vaccine at 8 weeks after baseline. This will be ascertained by clinic records of vaccine uptake. | 8 weeks following the first encounter | |
Primary | Uptake of HPV Self-collection Over the 8 weeks Follow-up | Proportion of eligible women who complete an HPV self-test at 8 weeks after baseline. This will be ascertained by laboratory receipt of self-collected specimens. | 8 weeks following the first encounter | |
Secondary | Intersectional Discrimination Index | HPV-and-cervical cancer associated stigma will be assessed using the Intersectional Discrimination Index measure. Higher scores mean greater stigma. | Measured at baseline and at 8 weeks | |
Secondary | Intervention Acceptability | This will be assessed using the Acceptability of Intervention Measure (AIM). The subscale is rated on a 5-point Likert scale, 1 to 5 with higher scores indicating higher levels of acceptability. | Measured at baseline and at 8 weeks | |
Secondary | Intervention Appropriateness | This will be assessed using the Intervention Appropriateness Measure (IAM). The subscale is rated on a 5-point Likert scale, 1 to 5 with higher scores indicating higher levels of Appropriateness. | Measured at baseline and at 8 weeks | |
Secondary | Intervention Feasibility | This will be assessed using the Feasibility of Intervention Measure (FIM). The subscale is rated on a 5-point Likert scale, 1 to 5 with higher scores indicating higher levels of feasibility. | Measured at baseline and at 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT01105000 -
Human Papilloma Virus (HPV) Knowledge and Attitudes and the Role of (SES) Socioeconomic Status and Ethnicity
|
||
Recruiting |
NCT06147388 -
Regression of Cervical Precancerous Lesions and Associated Risk Factors
|
||
Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT06109870 -
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
|
N/A | |
Completed |
NCT03082950 -
HPV Infections, Cancer of the Vulva and Therapeutical Success
|
||
Recruiting |
NCT01512784 -
Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults
|
Phase 3 | |
Recruiting |
NCT05363709 -
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
|
Phase 2 | |
Completed |
NCT01231945 -
Low-Cost Molecular Cervical Cancer Screening Study
|
N/A | |
Recruiting |
NCT01011712 -
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
|
||
Recruiting |
NCT05996016 -
Gut and Vaginal Microbiota Profile Study for HIV Women
|
||
Completed |
NCT05907187 -
Research in Ethno-Medicine and Education (REMED)
|
N/A | |
Completed |
NCT05616767 -
Prevention and Screening for Early Detection of HPV-related Cancers in Gay and Bisexual Men in Tanzania
|
N/A | |
Completed |
NCT02247999 -
Improving Cervical Cancer Screening Among HIV-Infected Women in India
|
||
Terminated |
NCT01468636 -
A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
|
Phase 4 | |
Active, not recruiting |
NCT04965792 -
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
|
||
Active, not recruiting |
NCT05006833 -
Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness
|
N/A | |
Enrolling by invitation |
NCT06120205 -
SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening
|
N/A | |
Recruiting |
NCT05208710 -
PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers
|
Early Phase 1 | |
Completed |
NCT05462249 -
Impact of Catch-up HPV Vaccination
|